XSHG
603168
Market cap332mUSD
Oct 09, Last price
6.04CNY
1D
1.51%
1Q
21.29%
Jan 2017
-73.91%
IPO
-71.64%
Name
Zhejiang Shapuaisi Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
4.91
EPS
—
Div yield, %
0.35%
Shrs. gr., 5y
3.07%
Rev. gr., 5y
5.82%
Revenues
460m
-4.92%
Net income
-239m
L+93.39%
CFO
45m
+75.01%
Dividend
Jun 13, 20240.021 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 2000 and is based in Pinghu, China.
Key people
Xiusong Lin
Chief Financial Officer, Deputy General Manager, Director · since 2024
Hongsheng Xu
Deputy General Manager · since 2024
Mingxiong Huang
Secretary of the Board, Director, Head of the General Manager's Office · since 2022
Hongli Lin
Chairman of the Board, General Manager · since 2024
Kai Lin
Director · since 2024
Weimin Wang
Director · since 2024
Jianguo Wu
Director · since 2024
Shengqun Chen
Independent Director · since 2024
Jiwei Sun
Independent Director · since 2022
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||